^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    COMPANY:
    Abbott

    i
    Other names: Abbott | KOS Pharma | Facet Biotech | Solvay | Ravizza Farmaceutici | CFR Pharma | Primal Healthcare | Alere Inc | St Jude Medical | Laboratorio Franco Colombiano Lafrancol | Lafrancol | Cytec | Veropharm | Laboratorios Recalcine | Fournier Pharma | Kos Pharmaceuticals | Kos Pharmaceuticals Inc | Kos Pharmaceuticals, Inc. | Kos Pharmaceuticals Inc. | Facet Biotech Corporation | Facet Biotech Corp | Solvay S.A. | Solvay SA | Solvay S A | Ravizza Farmaceutici SpA | CFR Pharmaceuticals | CFR Pharmaceuticals SA | CFR Pharmaceuticals S.A. | CFR Pharmaceuticals S A | Piramal Healthcare Ltd | Alere Inc. | Alere, Inc. | Alere, LLC | Alere LLC | St. Jude Medical, Inc. | Laboratorio Franco-Colombiano S.A.S. | Laboratorios Lafrancol | Laboratorio Franco Colombiano Lafrancol SA | Laboratorios Recalcine SA | Laboratorios Recalcine S.A. | Laboratorios Recalcine S A | Fournier Pharma Inc. | Fournier Industrie et Sante SAS | Fournier Pharma Corp | Abbott Laboratories | Abbott Diagnostics Division | Abbott Medical Devices | Abbott Diabetes Care | Abbott Labs | Abbott Laboratories, Inc | Abbott Laboratories Inc | Alere | Piramal Healthcare | Walk Vascular | Thoratec | Cephea Valve Technologies | Evalve Corporation | Evalve, Inc. | Ibis Biosciences | Endosense | Biosite | CardioMEMS | Cholestech | EP MedSystems | IDEV Technologies | Inverness Medical Innovations | Irvine Biomedical | Nanostim | NeuroTherm | Ostex International | Spinal Modulation, Inc. | Spinal Modulation Inc. | Tendyne Holdings | Therasense | Ventritex | Knoll Pharmaceuticals
    Related tests:
    Evidence

    News

    4ms
    FDA approves olutasidenib for relapsed or refractory acute myeloid leukemia with a susceptible IDH1 mutation (FDA)
    "...Food and Drug Administration (FDA) approved olutasidenib (Rezlidhia) capsules for adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test...FDA also approved the Abbott RealTime IDH1 Assay to select patients for olutasidenib."
    FDA event
    |
    Abbott RealTime IDH1